Ardent Health's Q1 Revenue Jumps 7%, Beats Estimates; Adjusted EBITDA Surges 26%
ARDT sits 30% above its 52-week low of $8.07.
Summary
Ardent Health, Inc. reported strong first-quarter results, with revenue increasing 7% year-over-year to $1.60 billion, surpassing analyst estimates of $1.58 billion. Adjusted EBITDA saw an even more significant rise of 26% year-over-year, reaching $124 million and comfortably beating the consensus estimate of $107.79 million. The company attributed growth to a 2% increase in adjusted admissions and a 5.5% rise in net patient service revenue per adjusted admission, alongside effective cost management. Furthermore, Ardent Health reaffirmed its full-year 2026 revenue guidance of $6.4 billion to $6.7 billion and adjusted EBITDA guidance of $485 million to $535 million, signaling confidence in its operational performance. These results indicate robust financial health and operational efficiency, likely leading to positive investor sentiment.
At the time of this announcement, ARDT was trading at $10.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $8.07 to $15.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.